Cupric chloride dihydrate — living evidence map

Summary

Copper is needed for hemoglobin synthesis, iron oxidation, cellular respiration and antioxidant defence; copper deficiency anemia is treated with oral or intravenous copper as copper gluconate, copper sulfate or copper chloride, and its blood effects reverse within 4 to 12 weeks while its nerve damage reverses only in part. · pmid:29959467

Identity

PubChem CID 61482: Cupric chloride dihydrate, Cl2CuH4O2, 170.48 g/mol. · pubchem:61482

IUPAC name: dichlorocopper;dihydrate. · pubchem:61482

Where the evidence actually sits

Proportion of the 1 claim about Cupric chloride dihydrate standing at each tier. Community volume is shown on the Consensus tab beside this and is never averaged into it.

Living evidence history

1 resolved citation, oldest to newest, coloured by tier. Retractions and contradictions land here as they are recorded.

Structure

No structure representation on record. PepJunkie draws only what an authoritative record supplies; for a peptide that is the residue sequence, and none has been curated for Cupric chloride dihydrate yet.

Dose evidence, rung by rung

A studied human dose exists on file. Open the rung: the dose is the paper's, in its context, never PepJunkie's.

1. Approved-label dose · a resolved regulatory document names a labelled dose

   nothing resolved on this rung

2. Studied human doses · resolved human studies at the established tier
   • Copper deficiency anemia: review article. · pmid 29959467 · 2018
3. Observational evidence · resolved human data at the emerging tier: thin, or contested

   nothing resolved on this rung

4. Community-reported protocols · protocol propositions from distinct members, counted once per human

   nothing resolved on this rung

5. Preclinical evidence · resolved animal, cell or mechanistic work

   nothing resolved on this rung

1 resolved citation, 0 unresolved (an unresolved citation lends nothing). Community volume is its own rung and is never averaged into the evidence rungs.